Showing 5161-5170 of 6808 results for "".
- Does IL-17 Play a Role in Skin Aging?https://practicaldermatology.com/news/does-il-17-play-a-role-in-skin-aging/2461770/Interleukin (IL)-17 may plays a central role in skin aging, according to research from Institute for Research in Biomedicine (IRB Barcelona) in collaboration with the National Center for Genomic Analysis (CNAG). The study, which was led by Dr. Guiomar Solanas, Dr. Salvador Azn
- Crown Laboratories Opens Expanded Production Facilityhttps://practicaldermatology.com/news/crown-laboratories-opens-expanded-production-facility/2461769/Crown Laboratories completed a 60,000-square-foot expansion at its manufacturing complex in Johnson City, Tennessee. A year in the making, the $7.5 million expansion project at Lafe Cox Drive increases manufacturing and warehouse space to support business growth. The appr
- Novartis Premieres New HS Docuseries at Tribeca Film Festivalhttps://practicaldermatology.com/news/novartis-premieres-new-hs-docuseries-at-tribeca-film-festival/2461768/Novartis is launching a new docuseries, "The Beacons: Illuminating HS Stories, in recognition of Hidradenitis Suppurativa (HS) Awareness Week. The series, which will premiere during the 2023 Tribeca Festival in New York, is part of the "Shine 
- Sol-Gel, Searchlight Pharma Partner to Commercialize TWYNEO and EPSOLAY in Canadahttps://practicaldermatology.com/news/sol-gel-searchlight-pharma-partner-to-commercialize-twyneo-and-epsolay-in-canada/2461764/Israel’s Sol-Gel Technologies, Ltd. and Searchlight Pharma Inc. have signed exclusive license agreements for TWYNEO and EPSOLAY for the Canadian market. Both products recently launched in the U.S., and Searchlight is to commercialize in Canada over a fifteen-year term that i
- Researchers Uncover Clues Driving PsO Spread and Severityhttps://practicaldermatology.com/news/researchers-uncover-clues-driving-pso-spread-and-severity/2461759/New research sheds light on the cellular changes that drive psoriasis severity and also offers important clues about how the disease spreads to other parts of the body. Specifically, the location of clusters of fibroblasts and macrophages tend to occur more commonly in the upper l
- Sun Pharma’s Ilumetri (Tildrakizumab Injection) Scores Nod For Plaque Psoriasis in Chinahttps://practicaldermatology.com/news/sun-pharmas-ilumetri-tildrakizumab-injection-scores-nod-for-plaque-psoriasis-in-china/2461753/The New Drug Application (NDA) of tildrakizumab injection under the brand name of Ilumetri has been approved by the National Medical Products Administration of the People’s Republic of China, Sun Pharma reports. Ilumetri is indicated for the treatment of adults wit
- Sun Pharma, Philogen Enter Into an Exclusive Distribution, License, and Supply Agreement for Nidlegy in Europe, Australia, and New Zealandhttps://practicaldermatology.com/news/sun-pharma-philogen-enter-into-an-exclusive-distribution-license-and-supply-agreement-for-nidlegy-in-europe-australia-and-new-zealand/2461752/Sun Pharmaceutical Industries has entered into a licensing agreement for commercializing Philogen’s Nidlegy (Daromun) in the territories of Europe, Australia and New Zealand. Nidlegy, currently in Phase III clinical trials, is a new anti-cancer biopharmaceutical which is bei
- Nivea's Skin Out Loud Series Tackles Skin Diversityhttps://practicaldermatology.com/news/niveas-skin-out-loud-series-tackles-skin-diversity/2461751/Nivea is rolling out a five-episode "Skin Out Loud" series. The series features a diverse cast of hosts including TV Host Milka Loff Fernandes, Brigiding from RuPaul's Drag Race Philippines, South African skinfluencer Zithobe
- DermBiont's 0.8% SM-030 Topical Gel Fades Solar Lentigos, Normalizes Pigmentation in Phase 2 Studyhttps://practicaldermatology.com/news/dermbionts-08-sm-030-topical-gel-fades-solar-lentigos-normalizes-pigmentation-in-phase-2-study/2461748/DermBiont’s 0.8% SM-030 gel performed well in a Phase 2 trial treating solar lentigos and normalizing pigmentation of the skin, the Company reports. SM-030 is a first-in-class selective and potent topical PKCβ inhibitor intended to reduce the production of epidermal mela
- Lumohs, George Tiemann and Company Join Forces to Distribute Lumohs’ Illuminating Devicehttps://practicaldermatology.com/news/lumohs-george-tiemann-and-company-join-forces-to-distribute-lumohs-illuminating-device/2461747/Nano Surgical is partnering with George Tiemann and Company, to bring Lumohs’ illuminating device to dermatology market. Lumohs is a patented, reusable scalpel handle that provides integrated shadowless illumination of the surgical site. With no light obstructions between th